Phase 2 Clinical Trial Initiates with First Post-Operative Patient Dosed

Orexa B.V., a Dutch firm dedicated to the advancement of pharmaceuticals, has initiated a Phase 2 clinical trial aimed at mitigating postoperative ileus in patients. The study, identified by the EudraCT number 2022-503113-31-00-IN-002, is designed to assess the impact of ORE-001, Orexa's flagship drug, on gastrointestinal function following major abdominal procedures.

The trial is structured as a multi-center, randomized, double-blind, placebo-controlled endeavor, targeting 100 to 120 female participants who are set to undergo gynecologic surgery involving a longitudinal laparotomy. The research is being conducted across various centers in Germany, with Prof. Alexander Mustae from the University Hospital Bonn (UKB) spearheading the investigation. The trial commenced on January 11, 2024, with the first patient receiving the treatment in Bonn.

Prof. Ard Peeters, a key figure at Orexa, emphasized the significance of this trial, marking a pivotal step for the company in advancing its clinical research. He highlighted the potential of ORE-001 to avert postoperative ileus, a condition that can impede the recovery process and prolong hospital stays for up to 50% of patients across different demographics.

Orexa's mission is to enhance food intake, which is crucial for the health and recovery of various patient populations. The company's primary focus is on aiding the recuperation of surgical patients, supporting those with anorexia, and addressing malnutrition issues such as sarcopenia and cachexia. Established in 2016, the company operates from its base in Herpen, North Brabant, Netherlands.